Santhera Pharmaceuticals Holding AG (0QN1.L)
CHF 9.79
(-0.81%)
CHF 9.79
(-0.81%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 25.06 Million CHF | -43.6% |
| 2022 | 44.43 Million CHF | 3.4% |
| 2021 | 42.97 Million CHF | -39.61% |
| 2020 | 71.16 Million CHF | 18.62% |
| 2019 | 59.99 Million CHF | 9.94% |
| 2018 | 54.56 Million CHF | 2.75% |
| 2017 | 53.11 Million CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | -100.0% |
| 2012 | 2.2 Million CHF | -1.52% |
| 2011 | 2.24 Million CHF | -1.41% |
| 2010 | 2.27 Million CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 0.0% |
| 2007 | - CHF | -100.0% |
| 2006 | 1.41 Million CHF | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 23.66 Million CHF | 11.44% |
| 2024 Q1 | 23.66 Million CHF | -5.57% |
| 2023 Q1 | 40.88 Million CHF | -7.99% |
| 2023 FY | 25.06 Million CHF | -43.6% |
| 2023 Q3 | 20.97 Million CHF | -49.46% |
| 2023 Q2 | 41.5 Million CHF | 1.52% |
| 2023 Q4 | 25.06 Million CHF | 19.47% |
| 2022 Q2 | 40.64 Million CHF | 1.68% |
| 2022 Q4 | 44.43 Million CHF | 1.42% |
| 2022 FY | 44.43 Million CHF | 3.4% |
| 2022 Q1 | 39.96 Million CHF | -7.0% |
| 2022 Q3 | 43.81 Million CHF | 7.81% |
| 2021 Q3 | 42.36 Million CHF | -2.3% |
| 2021 FY | 42.97 Million CHF | -39.61% |
| 2021 Q1 | 42.61 Million CHF | -40.11% |
| 2021 Q2 | 43.36 Million CHF | 1.76% |
| 2021 Q4 | 42.97 Million CHF | 1.44% |
| 2020 Q1 | 60.6 Million CHF | 1.02% |
| 2020 Q2 | 61.64 Million CHF | 1.71% |
| 2020 FY | 71.16 Million CHF | 18.62% |
| 2020 Q4 | 71.16 Million CHF | 1.09% |
| 2020 Q3 | 70.39 Million CHF | 14.2% |
| 2019 Q3 | 58.98 Million CHF | -7.92% |
| 2019 Q1 | 63.04 Million CHF | 15.52% |
| 2019 FY | 59.99 Million CHF | 9.94% |
| 2019 Q4 | 59.99 Million CHF | 1.72% |
| 2019 Q2 | 64.05 Million CHF | 1.61% |
| 2018 Q2 | 53.82 Million CHF | 0.0% |
| 2018 Q1 | 53.82 Million CHF | 1.34% |
| 2018 FY | 54.56 Million CHF | 2.75% |
| 2018 Q4 | 54.56 Million CHF | 0.69% |
| 2018 Q3 | 54.19 Million CHF | 0.68% |
| 2017 Q4 | 53.11 Million CHF | 0.0% |
| 2017 FY | 53.11 Million CHF | 0.0% |
| 2017 Q2 | 52.42 Million CHF | 0.0% |
| 2017 Q1 | 52.42 Million CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2015 Q3 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q3 | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2013 FY | - CHF | -100.0% |
| 2013 Q1 | - CHF | -100.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2012 Q4 | 2.2 Million CHF | 0.0% |
| 2012 Q3 | - CHF | -100.0% |
| 2012 FY | 2.2 Million CHF | -1.52% |
| 2012 Q2 | 2.22 Million CHF | 0.0% |
| 2011 FY | 2.24 Million CHF | -1.41% |
| 2011 Q2 | 2.25 Million CHF | 0.0% |
| 2011 Q4 | 2.24 Million CHF | 0.0% |
| 2010 Q4 | 2.27 Million CHF | 0.0% |
| 2010 FY | 2.27 Million CHF | 0.0% |
| 2010 Q2 | 2.28 Million CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 0.0% |
| 2007 FY | - CHF | -100.0% |
| 2006 FY | 1.41 Million CHF | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 4.31 Million CHF | -481.35% |
| Tecan Group AG | 316.09 Million CHF | 92.071% |
| Basilea Pharmaceutica AG | 128.6 Million CHF | 80.513% |
| Bachem Holding AG | 401 Thousand CHF | -6149.875% |
| Siegfried Holding AG | 525 Million CHF | 95.226% |
| Molecular Partners AG | 3.65 Million CHF | -586.254% |